apixaban

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• BMS picks Texas for new $2.3B manufacturing campus
  Bristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.
  biospace · 1d ago
• Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
  Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
  biopharma_dive · 6d ago
• No deal between AstraZeneca and BMS, senior source insists: Reuters
  Reuters has deflated rumors that AstraZeneca and Bristol Myers Squibb are discussing a possible merger, letting the air out of industry-wide speculation over what could have been the largest deal i…
  biospace · 6d ago
• Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
  The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second qu…
  biospace · 6d ago
• Pfizer CEO defends $7B bolt-on M&A strategy as peers rush to buy
  Asked on a second quarter earnings call if Pfizer could direct more money to M&A amid a feeding frenzy across the pharma industry, CEO Albert Bourla defended his strategy.
  biospace · 7d ago
• Pfizer expands multibillion-dollar cost-cutting plan
  Hatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.
  biopharma_dive · 7d ago
• As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
  While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…
  biospace · 7d ago
• Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
  The additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major…
  biospace · 7d ago
• An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
  In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.
  biopharma_dive · 8d ago
• Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
  Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patien…
  fiercebiotech · 9d ago